Fierce Pharma13h
Vanrafia, 2nd drug in Novartis' IgAN troika, crosses FDA finish line in payday for Chinook investors
When Novartis bought kidney disease biotech Chinook Therapeutics in 2023 for $3.2 billion upfront, the deal included a ...
NJ-based Novartis to lay off 427 as drug patent expires
Global drugmaker Novartis will lay off 427 employees in East Hanover this spring and summer, after it let go of 235 at the Morris County site last year, filings with the New Jersey Department of Labor ...
Pharma tariff relief likely short-lived with sector-specific duties on the horizon
Pharmaceutical companies breathed a sigh of relief on Wednesday, but the tariff reprieve could prove fleeting.
Novartis gets FDA accelerated approval for kidney disease treatment
Novartis ( NYSE: NVS) said on Thursday that it received US FDA's accelerated approval for Vanrafia as a treatment for adults ...
Fierce Pharma13d
Novartis snags FDA nod for Fabhalta in another kidney disease but leaves room for rival Apellis
Novartis' Fabhalta has become the first treatment approved by the FDA for the ultra-rare kidney disease C3G. But analysts ...
pharmaphorum11y
Novartis, BioE in typhoid vaccine deal
Novartis has entered into a development and licensing agreement with India-based Biological E Limited (BioE) for two vaccines to protect against typhoid and paratyphoid fevers. Novartis has a goal ...
pharmaphorum2d
Novartis debuts $1-a-month drug access programme in Kenya
Novartis has started the first phase of a programme that will make 15 of its essential medicines available in lower-income countries for just $1 per drug per month. The Novartis Access scheme ...
Novartis14d
Novartis receives third FDA approval for oral Fabhalta® (iptacopan) – the first and only treatment approved in C3 glomerulopathy (C3G)
Basel, March 20, 2025 – Novartis today announced that oral Fabhalta ® (iptacopan) has received U.S. Food and Drug Administration (FDA) approval for the treatment of adults with C3 glomerulopathy (C3G) ...
Yahoo Finance14d
Novartis receives third FDA approval for oral Fabhalta® (iptacopan) - the first and only treatment approved in C3 glomerulopathy (C3G)
EAST HANOVER, N.J., March 20, 2025 /PRNewswire/ -- Novartis today announced that oral Fabhalta ® (iptacopan) has received U.S. Food and Drug Administration (FDA) approval for the treatment of ...